Literature DB >> 2902806

Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria.

T Ishikawa1, M Yanagisawa, S Kimura, K Goto, T Masaki.   

Abstract

Endothelin (ET), a novel 21-amino acid peptide isolated from the culture supernatant of porcine aortic endothelial cells, has been shown to be the most potent of all known vasoconstrictor substances. The purpose of the present study was to investigate the effects and the mode of actions of ET on the heart. ET exerted a positive inotropic effect in a dose-dependent manner on the electrically driven left atria of guinea pigs. The ET-induced response was of slow onset and characteristically long lasting. The half-maximal effective dose of the ET-induced response was about 1 nM, indicating that ET is one of the most potent cardiotonic substances. The response was presumably caused through direct actions of ET on the myocytes, since adrenergic, histaminergic, and serotonergic antagonists showed no effect on the response. The dose-response relationship of ET for the positive inotropic effect was displaced to the right in a parallel fashion by 0.3 microM nicardipine. In the left atria depolarized with 22 mM KCl, ET produced gradually increasing contractions in conjunction with the slow response action potentials in response to the electrical pacing. These results suggest that the ET-induced response on the left atria is intimately related to the influx of extracellular Ca2+.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902806     DOI: 10.1152/ajpheart.1988.255.4.H970

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  62 in total

1.  Endothelin causes contraction of canine and bovine arterial smooth muscle in vitro and in vivo.

Authors:  Y Suzuki; S Satoh; I Ikegaki; T Asano; M Shibuya; K Sugita; K Lederis; O Rorstad
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway.

Authors:  R A Kelly; H Eid; B K Krämer; M O'Neill; B T Liang; M Reers; T W Smith
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

Review 3.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

4.  Endothelial cells regulate cardiac contractility.

Authors:  C Ramaciotti; A Sharkey; G McClellan; S Winegrad
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Endothelin activates voltage-dependent Ca2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes.

Authors:  M R Lauer; M D Gunn; W T Clusin
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

6.  Nifedipine and experimental cardioprotection.

Authors:  W G Nayler; J J Liu; S Panagiotopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Effect of cromakalim (BRL 34915) on hemodynamic and electrocardiographic changes induced by endothelin in dogs.

Authors:  T Tsunetoshi; A Otsuka; H Mikami; K Katahira; A Moriguchi; T Ogihara
Journal:  Basic Res Cardiol       Date:  1991 Jan-Feb       Impact factor: 17.165

8.  Pharmacological characteristics of endothelin receptors in the rabbit ventricular myocardium: the nonselective endothelin receptor antagonist PD 145065 antagonizes the positive inotropic effect of endothelin-3 but not of endothelin-1.

Authors:  I Norota; M Endoh
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

9.  The pharmacological properties of the peptide, endothelin.

Authors:  R M Eglen; A D Michel; N A Sharif; S R Swank; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

Review 10.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.